However, based on the link between MDS and AML-MRC in terms of potential pathways and genetic biomarkers [41,42,43] and similar molecular characteristics described here and in several preceding papers, it is evident that MDS and AML-MRC share important features on the biological level, enabling the application of similar therapeutic approaches that specifically address both of these pathological entities. The gene discussed is CD200; the disease is myelodysplastic syndrome.